Valuation
- Market cap
- 63,154,000
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 27,700
- Avg volume
- 4,884
- Day's range
- $1.26 – $1.30
- Shares out
- 48,580,000
- Stochastic %K
- 71%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $3.00
Company profile
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpati...
Show more
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 346 396 4770
- Website
- https://www.nuot.com
- Address
- 8285 El Rio, Suite 190, Houston, United States
Latest news
No headlines yet.
